Gastrointestinal Cancer and Gastric Cancer

The GI Cancer Channel on VJOncology is supported by Seagen. This supporter has no influence over the production of the content.

View overview page
0:27
RATIONALE-305: tislelizumab + chemo vs placebo +chemo in advanced GC/GEJC
Tania C. Fleitas • 22 Oct 2023
1:45
1L nivo + low dose ipi in pts with advanced gastric or esophago-gastric junction MSI-H tumors
Kei Muro • 23 Oct 2023
8:01
INNOVATION: chemotherapy with trastuzumab and pertuzumab in HER2+ gastric cancer
Anna Wagner • 29 Jun 2023
2:17
Claudin 18.2 and FGFR2b as novel targets in gastric cancer
Filippo Pietrantonio • 29 Jun 2023
0:53
The future of ADCs in gastric and colorectal cancers
Kristen Ciombor • 30 Jun 2023
5:14
KEYNOTE-859: pembrolizumab plus chemotherapy in G/GEJ adenocarcinoma
Lucjan Wyrwicz • 29 Jun 2023
1:03
Novel treatments for gastric cancer
Kohei Shitara • 3 Jun 2023
1:52
IILUSTRO: zolbetuximab, mFOLFOX6, and nivolumab combinations for gastrointestinal cancer
Kohei Shitara • 3 Jun 2023
1:07
Claudin 18.2: a biomarker for gastric cancer
Kohei Shitara • 3 Jun 2023
3:23
Antibody-drug conjugates in the treatment of solid tumors
Kohei Shitara • 3 Jun 2023
2:42
Overcoming the challenges faced in identifying novel targets for ADC development
Valentina Boni • 4 Jun 2023
1:02
Advancing ADC therapy
Valentina Boni • 4 Jun 2023
1:37
Microsatellite instability screening in gastric and GEJ cancers
Filippo Pietrantonio • 29 Jun 2023
2:09
Evaluating the optimal approach for managing MSI-H upper GI cancers
Filippo Pietrantonio • 29 Jun 2023
0:48
TROPION-PanTumor03: datopotamab deruxtecan in advanced solid tumors
Kristen Ciombor • 30 Jun 2023
1:35
Assessing the prevalence of CLDN18.2 in gastric/gastroesophageal cancers
Kohei Shitara • 5 Jun 2023

The GI Cancer Channel on VJOncology is supported by Seagen.

This supporter has no influence over the production of the content.

The content of VJOncology is intended for healthcare professionals